Xeris Biopharma Holdings, Inc.

XERS Nasdaq SEC CIK 1867096
Follow Xeris Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $107.2M +44.2% vs same quarter last year
Net income $11.3M +1718% vs same quarter last year
EPS, diluted $0.06
Operating cash flow $35.5M +92.4% vs same quarter last year
Revenue by quarter
$60.1M
$60.1M
$71.5M
$74.4M
$85.8M
$83.1M
$92.1M
$107.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$291.8M$554K
FY24$203.1M−$54.8M
FY23$163.9M−$62.3M
FY22$110.2M−$94.7M
FY21$49.6M−$122.7M
FY20$20.2M−$91.1M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY258.5%0.2%
FY24−16.6%−27%
FY23−26.8%−38%
FY22−74.3%−85.9%
FY21−232.2%−247.5%
FY20−414.5%−452.2%
FY19--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Xeris Biopharma
  • Healthcare median
−600%−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearXeris BiopharmaHealthcare median
FY250.2%−30.6%
FY24−27%−47%
FY23−38%−58%
FY22−85.9%−80.4%
FY21−247.5%−71.9%
FY20−452.2%−62.2%
FY19-−46.3%